Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 5/20 | 0.37 |
| ▸ | TNK2 | Q07912 | 3/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1003055 | 0.81 | P2RX3 (0.42) | MEN1KMT2AMCHR1HRH3KCNH2 | |
| SCHEMBL2892007 | 0.80 | MCHR1 (0.62) | MCHR1KCNH2 | |
| SCHEMBL1002650 | 0.79 | MEN1 (0.45) | MEN1KMT2AMCHR1KCNH2 | |
| SCHEMBL2895097 | 0.79 | MCHR1 (0.59) | MCHR1HRH3KCNH2 | |
| SCHEMBL15093765 | 0.77 | MEN1 (0.43) | MEN1KMT2ATNK2HSD11B1PTPN1 | |
| SCHEMBL15093959 | 0.77 | MEN1 (0.43) | MEN1KMT2ATNK2HSD11B1PTPN1 | |
| SCHEMBL222919 | 0.77 | MEN1 (0.43) | MEN1KMT2ATNK2HSD11B1PTPN1 | |
| SCHEMBL2893455 | 0.77 | PDE4B (0.39) | MEN1KMT2AMCHR1TNK2HRH3 | |
| SCHEMBL2893456 | 0.77 | PDE4B (0.39) | MEN1KMT2AMCHR1TNK2HRH3 | |
| SCHEMBL5267094 | 0.77 | MCHR1 (0.56) | MCHR1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7732456-B2 | Pyridone derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-06-08 | — | — | US | disclosed |
| US-20070208046-A1 | Pyridone derivative | MSD K.K. (JP) | 2007-09-06 | — | — | US | disclosed |
| EP-1741703-A1 | PYRIDONE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-01-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208046-A1 | Pyridone derivative | CHRM1, XDH, MTR | MEN1 616/4885KMT2A 2416/4885MCHR1 535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.